Lysosomal Storage Diseases  >>  Replagal (agalsidase alfa)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
NCT00357786: An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease

Completed
1
3
US
Replagal agalsidase alfa, Replagal
National Institute of Neurological Disorders and Stroke (NINDS)
Fabry Disease
12/08
 

Download Options